Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 1/20 | 0.41 |
| ▸ | FOLH1 | Q04609 | 8/20 | 0.41 |
| ▸ | NAALAD2 | Q9Y3Q0 | 3/20 | 0.41 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 3/20 | 0.38 |
| ▸ | PPARA | Q07869 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.38 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | PPARD | Q03181 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5527994 | 1.00 | TGFBR1 (0.41) | TGFBR1FOLH1NAALAD2RIMKLAMAPK1 | |
| SCHEMBL16001107 | 0.88 | ITGB1 (0.48) | TGFBR1FOLH1NAALAD2RIMKLAPPARG | |
| SCHEMBL14537500 | 0.84 | FOLH1 (0.38) | TGFBR1FOLH1NAALAD2RIMKLAMAPK1 | |
| SCHEMBL14932838 | 0.83 | GAA (0.33) | FOLH1MAPK1ALDH1A1 | |
| SCHEMBL1983218 | 0.82 | MAPK1 (0.54) | FOLH1MAPK1LMNAALDH1A1 | |
| SCHEMBL1983219 | 0.82 | MAPK1 (0.54) | FOLH1MAPK1LMNAALDH1A1 | |
| SCHEMBL4462156 | 0.81 | TGFBR1 (0.37) | TGFBR1FOLH1NAALAD2RIMKLAPPARG | |
| SCHEMBL4461437 | 0.81 | TGFBR1 (0.37) | TGFBR1FOLH1NAALAD2RIMKLAPPARG | |
| SCHEMBL46641 | 0.81 | PPARA (0.57) | PPARGPPARAPPARD | |
| SCHEMBL2313666 | 0.81 | PPARA (0.57) | PPARGPPARAPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140194349-A1 | HIV Protease Inhibiting Compounds | ABBVIE INC. (US) | 2014-07-10 | — | — | US | disclosed |
| EP-1697344-B1 | HIV PROTEASE INHIBITING COMPOUNDS | ABBOTT LAB (US) | 2011-09-28 | — | — | EP | disclosed |
| EP-2266971-A2 | Hiv protease inhibiting compounds | Abbott Laboratories (US) | 2010-12-29 | — | — | EP | disclosed |
| US-7834043-B2 | Prevent reproduct of aids virus | ABBOTT LABORATORIES (US) | 2010-11-16 | — | — | US | disclosed |
| US-20100249181-A1 | HIV Protease Inhibiting Compounds | ABBOTT LABORATORIES (US) | 2010-09-30 | — | — | US | disclosed |
| EP-1697344-A2 | HIV PROTEASE INHIBITING COMPOUNDS | ABBOTT LABORATORIES (US) | 2006-09-06 | — | — | EP | disclosed |
| US-20050148623-A1 | Prevent reproduct of aids virus | ABBVIE INC. | 2005-07-07 | — | — | US | disclosed |
| WO-2005058841-A2 | HIV PROTEASE INHIBITING COMPOUNDS | ABBOTT LABORATORIES (US) | 2005-06-30 | — | — | WO | disclosed |
| EP-0900210-B1 | ANTIVIRALLY ACTIVE HETEROCYCLIC AZAHEXANE DERIVATIVES | NOVARTIS AG (CH) | 2005-02-09 | — | — | EP | disclosed |
| US-6300519-B1 | REACTING HYDRAZINE DERIVATIVE WITH EPOXIDE COMPOUND | NOVARTIS FINANCE CORPORATION | 2001-10-09 | — | — | US | disclosed |
| US-6166004-A | Combinations of HIV protease inhibitors with reverse transcriptase inhibitors | NOVARTIS FINANCE CORPORATION (US) | 2000-12-26 | — | — | US | disclosed |
| US-6110946-A | AN ENZYME INHIBITORS OF RETROVIRAL ASPARTATE PROTEASE FOR THE TREATMENT OF AIDS | NOVARTIS FINANCE CORPORATION (US) | 2000-08-29 | — | — | US | disclosed |
| EP-0900210-A1 | ANTIVIRALLY ACTIVE HETEROCYCLIC AZAHEXANE DERIVATIVES | Novartis AG (CH) | 1999-03-10 | — | — | EP | disclosed |
| US-5849911-A | Antivirally active heterocyclic azahexane derivatives | NOVARTIS FINANCE CORPORATION (US) | 1998-12-15 | — | — | US | disclosed |
| WO-1997040029-A1 | ANTIVIRALLY ACTIVE HETEROCYCLIC AZAHEXANE DERIVATIVES | NOVARTIS AG (CH) | 1997-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148623-A1 | Prevent reproduct of aids virus | SERPINB1, PRSS1, SERPINA3 | TGFBR1 4117/4885FOLH1 1375/4885NAALAD2 208/4885 |
| US-20100249181-A1 | HIV Protease Inhibiting Compounds | SERPINB1, HPN, DNPEP | TGFBR1 4610/4885FOLH1 252/4885NAALAD2 28/4885 |
| US-20140194349-A1 | HIV Protease Inhibiting Compounds | SERPINB1, HPN, DNPEP | TGFBR1 4610/4885FOLH1 252/4885NAALAD2 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.